Catabasis Pharmaceuticals enters collaboration with Sarepta Therapeutics

Catabasis Pharmaceuticals Inc. (Nasdaq: CATB) entered a joint research collaboration with Sarepta Therapeutics (Nasdaq: SRPT) to explore a combination drug treatment approach for Duchenne muscular dystrophy. Shares of Catabasis Pharmaceuticals surged $1.77 to close at $6.25 while Sarepta Therapeutics stock dropped $1.26 to close at $60.98.



Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.